End-Stage Liver Disease and Coagulopathy

Introduction

• Advanced liver disease is associated with complex pathophysiologic alterations in hemostasis. By the time ESLD is manifested, there is a disruption in the synthesis of coagulation factors, natural anticoagulation proteins, and fibrinolytic regulators. Traditionally, patients with ESLD have been considered globally hypocoagulable due to thrombocytopenia and elevated international normalized ratio (INR) values. However, emerging evidence indicates that these laboratory abnormalities correlate poorly with actual bleeding risk during invasive procedures.¹
• Despite extensive derangements in the hemostatic system, many patients with ESLD maintain a state of “rebalanced” clotting equilibrium.² Moreover, chronic inflammation, portal hypertension, and venous congestion further modulate peripheral hemostatic mechanisms, at times, predisposing patients to a hypercoagulable state. This tenuous balance is easily disrupted, underscoring the importance of understanding the dynamic mechanisms underlying coagulopathy in liver disease to facilitate accurate diagnosis and management (Figure 1).

Hemostasis and ESLD

• The hemostatic process can be conceptualized as occurring in three interconnected phases: (1) primary hemostasis with platelet aggregation and activation, (2) secondary hemostasis with coagulation, and (3) fibrinolysis.³
• Hemostasis is influenced by multiple factors, including plasma concentrations of the coagulation factors and the integrity of the endothelial milieu.
• Although emerging evidence indicates that patients with cirrhosis may maintain near-normal global coagulation, this fragile equilibrium is easily disrupted in the perioperative setting.⁴
  • Thrombocytopenia: reduced hepatic synthesis of thrombopoietin leads to decreased platelet reduction. Portal hypertension contributes to blood diversion to the spleen and subsequent splenic sequestration of platelets.
    Chronic inflammation promotes endothelial release of von Willibrand factor (vWF), enhancing platelet aggregation and clot formation.
  • Coagulation factors: the liver is responsible for synthesizing the majority of procoagulation factors, (e.g., fibrinogen (I), prothrombin (II) and factors V, VII, VIII, IX, X, XI, and XII) as well as the natural anticoagulation protein C, protein S, and antithrombin. In ESLD, impaired hepatic synthetic function results in decreased production of both these pro- and anticoagulant factors.
  • Fibrinolysis: circulating tissue plasminogen activator (tPA) levels are elevated due to increased endothelial release and reduced hepatic clearance. The liver synthesizes several antifibrinolytic proteins, including plasminogen, alpha-2 antiplasmin, thrombin-activatable fibrinolysis inhibitor (TAFI), and factor XIII, levels of which are all decreased in ESLD.⁴

Laboratory Testing^5,6

• Conventional laboratory assays – such as prothrombin time, INR, and platelet count (PLT) –provide an incomplete assessment of hemostasis in patients with cirrhosis/ESLD.
• Patients with ESLD often demonstrate elevated plasma levels of thrombomodulin, a thrombin cofactor that activates protein C and theoretically promotes hypocoagulability. However, they usually exhibit relative resistance to thrombomodulin, mitigating this anticoagulant effect. Concurrently, levels of factor VIII, a potent enhancer of thrombin generation, are frequently raised, further complicating the balance of hemostasis.
• Thrombocytopenia is often an early manifestation of cirrhosis and contributes to an increased risk of bleeding. However, this effect is counterbalanced by elevated circulating levels of vWF and factor VIII, which enhance platelet adhesion and promote coagulation.
• Consequently, global assays that evaluate overall clot dynamics – such as VET – provide a more accurate reflection of the actual coagulation status (Figure 2).

Products Used for Hemostasis Management

• Fresh frozen plasma (FFP) is not routinely recommended for the correction of coagulopathy in ESLD. It delivers both procoagulant and anticoagulant factors, and elevations in INR correlate poorly with the risk of bleeding. Furthermore, the large infusion volumes required can cause volume overload and exacerbate portal hypertension. FFP use should therefore be reserved for active bleeding or urgent invasive procedures in patients with significant coagulopathy.⁷
• Cryoprecipitate transfusion is the preferred method for increasing fibrinogen levels in patients with ESLD, as it minimizes the risk of volume overload. Its administration should be guided by documented hypofibrinogenemia and VET results.
• Prothrombin complex concentrate is a low-volume alternative to FFP or cryoprecipitate. It may be used when rapid hemostatic control is required, such as during invasive procedures or active bleeding episodes.
• PLT transfusion should be considered in patients who demonstrate evidence of a bleeding diathesis, when the overall clinical context supports the need for hemostatic intervention. In patients with ESLD, thrombopoietin receptor agonists may be employed to safely increase PLTs to clinically acceptable thresholds, thereby reducing the need for transfusion.
• Vitamin K plays an essential role in hepatic synthesis of the vitamin K-dependent clotting factors—prothrombin (Factor II), Factor VII, Factor IX, and Factor X—as well as the natural anticoagulants, proteins C and S. In patients with a complete loss of hepatic synthetic capacity, vitamin K administration is unlikely to provide any benefit. However, as most individuals with ESLD retain some degree of residual hepatic function, vitamin K supplementation is a low-risk intervention that may support coagulation.
• Recombinant activated factor VII (rFVIIa) is a potent procoagulant that promotes a rapid “thrombin burst,” facilitating hemostasis in the setting of severe or diffuse coagulopathy. Although it can effectively enhance clot formation, its use is associated with an increased risk of thromboembolic complications. Consequently, rFVIIa is used infrequently in liver transplantation and is generally reserved for cases of refractory bleeding unresponsive to conventional hemostatic measures.
• Anticoagulation therapy is indicated in patients with portal vein thrombosis (PVT), splanchnic vein thrombosis, or venous thromboembolism. Evidence suggests that appropriate anticoagulation not only promotes venous recanalization but may also improve overall survival, particularly among patients who are candidates for liver transplantation. Low-molecular-weight heparin is generally preferred in patients with cirrhosis due to its favorable safety profile and predictable pharmacokinetics. In patients with compensated liver disease, transition to oral anticoagulation with warfarin or a direct oral anticoagulant may be appropriate for long-term maintenance therapy, provided hepatic function and bleeding risk are carefully monitored. tPA is a fibrinolytic agent that facilitates clot dissolution by converting plasminogen to plasmin. In the intraoperative setting, tPA is most commonly administered in cases of massive pulmonary embolism, PVT, or hepatic artery thrombosis, where rapid restoration of blood flow is critical to preserve organ perfusion and function.
• Antifibrinolytic agents are utilized in the management of bleeding related to hyperfibrinolysis, a condition that occurs in up to half of patients with ESLD undergoing surgery. This phenomenon is typically characterized by persistent diffuse, mucosal or venous oozing. Tranexamic acid (TXA) and ε-aminocaproic acid may be considered for the acute management of refractory bleeding secondary to hyperfibrinolysis—a diagnosis that is often made on clinical grounds rather than through laboratory confirmation.

Special Considerations in Liver Disease

• In patients with acute liver failure (ALF), the INR is often markedly elevated. Despite this, VET frequently demonstrates normal or even hypercoagulable profiles. Thrombocytopenia in ALF is primarily driven by platelet activation in the context of a systemic inflammatory response syndrome. The degree of PLT reduction is generally less pronounced than that observed in chronic or acute-on-chronic liver failure. Notably, platelet activation may contribute to a hypercoagulable state; however, this process can also precipitate a consumptive coagulopathy in certain cases.
• Unlike individuals with isolated coagulation factor deficiencies, patients with chronic liver failure infrequently present with a bleeding diathesis. Levels of circulating von Willebrand factor (vWF) and factor VIII are typically elevated, enhancing both platelet aggregation and thrombin generation. As a result, it is not uncommon for patients with ESLD to demonstrate normal initial clot formation times—such as the R-time on TEG or the CFT on ROTEM—despite INR values of 2 or greater.
• Routine prophylactic transfusion of FFP or platelets is generally not recommended in patients with ESLD undergoing surgery. Evidence indicates that such transfusions do not reliably reduce bleeding risk and may, in fact, expose patients to potential harm.⁸
• For patients with ESLD undergoing high-risk procedures, commonly used transfusion thresholds include a PLT greater than 50,000/µL and a fibrinogen level above 120 mg/dL. In contrast, commonly cited INR targets for correction lack robust evidence in the liver failure population.^9,10

Coagulopathy Management During Liver Transplantation^11,12

• Intraoperative coagulation management during liver transplantation is a key aspect of anesthetic and surgical care, requiring close collaboration between teams. Coagulation dynamics are influenced by blood loss, dilutional effects, and impaired hepatic synthesis of clotting factors. Disruption of the liver’s central role in coagulation and fibrinolysis necessitates continuous monitoring to guide timely intervention and prevent adverse outcomes.
• Real-time coagulation assessment with VET enables the targeted correction of coagulation abnormalities; however, rapid intraoperative changes often necessitate prompt clinical judgment and close coordination with the surgical team. Transfusion management—using PRBCs, FFP, PLT, and cryoprecipitate—is guided by VET results and hemodynamic status, aiming to maintain hemostasis while avoiding over-transfusion and volume overload. When severe coagulopathy occurs, damage control resuscitation may be required to stabilize the patient and restore coagulation balance (Figure 3).
• In addition to transfusion support, antifibrinolytics such as TXA may be used to prevent hyperfibrinolysis, which commonly occurs during the anhepatic and reperfusion phases of liver transplantation. Maintaining normothermia, correcting acidosis and hypocalcemia, and optimizing hemodynamics are essential to preserve coagulation and support graft viability.
• Consumptive coagulopathy during liver transplantation results from extensive activation of the coagulation cascade triggered by tissue injury, inflammation, and release of procoagulant material from the diseased or reperfused liver. This leads to depletion of clotting factors and platelets, worsening bleeding despite apparent hypercoagulability. Early recognition using dynamic coagulation monitoring enables targeted replacement therapy while avoiding excessive transfusion and secondary microvascular thrombosis.
• Use of expanded donor criteria grafts—including older, steatotic, or donation-after-circulatory-death livers—complicates intraoperative coagulation management due to increased ischemia-reperfusion injury and risk of coagulopathy. Reperfusion may trigger release of procoagulant and fibrinolytic mediators, heightening both bleeding and thrombotic risk. Individualized coagulation and thrombosis management is therefore essential to optimize graft function and patient outcomes.
• PLT count recovery after liver transplantation is often delayed, requiring close monitoring for both bleeding and thrombotic events. PVT remains a significant postoperative risk, as it can impair graft perfusion and lead to dysfunction or failure. Vigilant surveillance of platelet trends and early detection of thrombosis are essential to prevent graft compromise and optimize post-transplant outcomes.